Clinical Trial Update: LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial comparing LCZ696 (sacubitril/valsartan) with valsartan in chronic heart failure patients with preserved ejection fraction. Results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan) (sacubitril/valsartan)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2015-08-13